A prospective multicenter study found high response rates with first-line obinutuzumab plus bendamustine across several indolent B-cell lymphoma subtypes, although short follow-up and the absence of a comparator limit conclusions about long-term benefit.
Milind Desai, MD, MBA, explains the domino effect linking obesity, obstructive sleep apnea, and hypertrophic cardiomyopathy—and why treating obesity may break the chain.
An ifosfamide shortage prompts cancer treatment concerns and new importation efforts.
This issue's content reflects a specialty that is clinically rigorous and structurally evolving.
Blood Cancer Awareness Month spotlights types of blood cancer and how pharmacists flag multiple myeloma symptoms early, speeding referral and care.
A prespecified analysis found the PCSK9 inhibitor reduced total events 20% in high-risk patients with no prior heart attack or stroke.
State boards of pharmacy are at the center of this issue and must be positioned and resourced to protect patient safety first.
In an interview with Pharmacy Times, Claudia R. Morris, MD, lead investigator and author of the phase 3 Sickle Cell Disease Treatment With Arginine Therapy (STArT) trial and a pediatric emergency medicine physician at Children’s Healthcare of Atlanta, discussed how treatment timing and patient heterogeneity may inform the design of future sickle cell pain trials.
Independent pharmacies should build documentation, watch rule making, and pressing for transparency terms in every contract renewal.
Zilganersen, an antisense oligonucleotide targeting glial fibrillary acidic protein, is cleared for pediatric and adult patients across all ages.
Pediatric and obstetric groups expand high-risk criteria and extend vaccination windows as federal vaccine guidance remains unsettled.
A real-world analysis of matched adults links glucagon-like peptide-1 (GLP-1) receptor agonist use to fewer major cardiovascular events, driven by a mortality benefit.
A minimum agreed set of outcomes could let pharmacists compare chronic kidney disease (CKD) interventions head-to-head and cut the heterogeneity that has long muddied trials.
Trial investigator Claudia R. Morris, MD, said substantial variation in pain phenotypes, treatment practices, and trial end points may offer broader lessons for future acute sickle cell disease research.
Both virtual and in-person interviews have their benefits.
In an interview with Pharmacy Times, Claudia R. Morris, MD, lead investigator and author of the phase 3 STArT trial and a pediatric emergency medicine physician at Children’s Healthcare of Atlanta, discussed how patient history and institutional pain-management practices may influence time to crisis resolution and how care teams, including pharmacists, can help standardize treatment.
This episode covers the importance of considering vaccine timing, selection, and hesitancy in patients on immunomodulating and immunosuppressive therapies, along with emerging data linking several vaccines to reduced dementia risk.
Time-to-vaccination data from a large diabetes cohort reveal delayed, incomplete uptake of pneumococcal vaccination, with age and citizenship emerging as the strongest predictors.
The phase 3 findings support MR-107A-02's potential as a nonopioid option for certain patients with moderate to severe acute pain.
Five "essential" outcomes, including medication error and adherence, should anchor every pharmacist intervention study in chronic kidney disease.
Melissa Seifert, PharmD, of UPMC Health Plan, explains how managed care pharmacists guide DMT selection and address adherence barriers in patients with MS.
A clinical pharmacy specialist at UPMC Health Plan discusses how pharmacists help select disease-modifying therapies, address adherence barriers, and coordinate whole-person care for those with MS.
In an interview with Pharmacy Times, Claudia R. Morris, MD, lead investigator and author of the phase 3 STArT trial, discusses why intravenous arginine did not shorten time to crisis resolution and how institutional variation, pain heterogeneity, shorter hospital stays, and treatment timing may have influenced the findings.
Glucagon-like peptide-1 (GLP-1) and GIP/GLP-1 agents are just the start: amylin- and glucagon-based mono-, dual-, and tri-therapies are on the horizon.
A subsequent dispute between state and federal officials over the deaths' classification has thrust the state into the center of a national vaccine policy fight.
A multicohort study finds divergent complication patterns and raises the prospect that millions are being treated for the wrong mechanism.
This FAQ describes what oncology pharmacists should know ahead of Gynecologic Cancer Awareness Month in September.
In an interview with Pharmacy Times, Claudia R. Morris, MD, lead author of the phase 3 STArT trial and professor of pediatrics and emergency medicine at Emory University School of Medicine, discusses findings from the phase 3 STArT trial of intravenous arginine for acute sickle cell pain, limitations of time to crisis resolution as a clinical trial end point, and opportunities for pharmacists to improve opioid-use data collection.
Pharmacists’ medication expertise can mitigate GI adverse effects and improve outcomes for patients beginning obesity pharmacotherapy
A Medicare GLP-1 bridge program marks 2026, while multiagonists like CagriSema are poised to lead the next wave of obesity therapy.
